AboutChad Giese

As the leader of the cardiovascular team, Chad develops Sg2’s cardiovascular intelligence and strategic insights to help members navigate the current landscape and future projections for CV services. He works closely with members via calls, webinars, retreat facilitation and consulting engagements to help inform and advise future strategic direction on cardiovascular service line topics that include program expansion, technology adoption and care redesign opportunities.

Prior to joining Sg2, Chad spent 14 years in the medical device industry with Medtronic. He spent 8 years in Medtronic’s cardiac rhythm disease management research department identifying novel uses for approved pacemakers and implantable cardioverter defibrillators, as well as making significant advancements in the area of 3D imaging. He also worked in the neuromodulation division for 6 years managing large clinical trials that generated pivotal clinical data necessary for FDA approval of implantable devices. His work generated 14 patents, 3 publications and multiple internal company awards of excellence. In 2013, he was listed as one of Minnesota’s top 500 inventors by the Twin Cities Business Journal.

Chad earned an MBA from DePaul University in Illinois and a BA in biology from Middlebury College in Vermont. He understands the value of cardiovascular health from being a professional cross-country skier for nearly a decade after college. He has represented the US at World Cup competitions and was a US national champion.

"Analytics and expertise to help you understand market dynamics and capitalize opportunities for growth."

As of February 11, 2016, Vizient, Inc. has completed its purchase of MedAssets Sg2 and spend and clinical resource management segments from Pamplona Capital Management, LLC. MedAssets revenue cycle business will continue to operate as a wholly-owned subsidiary of Pamplona Capital Management LLP.

Follow Sg2 on Facebook Follow Sg2 on Twitter Connect with Sg2 on LinkedIn Watch Sg2 on YouTube